You are here

  • Home
  • Online First
  • Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?

Article info

Article menu

other Versions

Download PDFPDF
Letter
Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?

Authors

  • Nicole Concin Department of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck, AustriaDepartment of Gynecology and Gynecological Oncology, Evangelische Kliniken Essen-Mitte, Essen, Germany PubMed articlesGoogle scholar articles
  • Xavier Matias-Guiu Department of Pathology, Hospital Universitari Arnau de Vilanova, University of Lleida, CIBERONC, Irblleida, SpainDepartment of Pathology, Hospital Universitari de Bellvitge, University of Barcelona, Idibell, Spain PubMed articlesGoogle scholar articles
  • Carien L Creutzberg Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands PubMed articlesGoogle scholar articles
  • on behalf of the ESGO-ESTRO-ESP Endometrial Carcinoma Guideline Working Group
    Google scholar articles
  1. Correspondence to Nicole Concin, Department of Gynecology and Obstetrics, Innsbruck Medical University, 6020 Innsbruck, Austria; nicole.concin{at}i-med.ac.at

Citation

Concin N, Matias-Guiu X, Creutzberg CL on behalf of the ESGO-ESTRO-ESP Endometrial Carcinoma Guideline Working Group
Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?
International Journal of Gynecologic Cancer Published Online First: 28 April 2021. doi: 10.1136/ijgc-2021-002668

Publication history

  • Accepted April 5, 2021
  • First published April 28, 2021.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.